Bank of America
AEGR

Bank of America’s Aegerion Pharmaceuticals AEGR Stock Holding History

Bank of America’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-83,600
Closed -$1.75M – 7916
2014
Q4 		$1.75M Buy
83,600
+53,200
+175% +$1.34M ﹤0.01% 3516
2014
Q3 		$1.01M Buy
30,400
+900
+3% +$27.9K ﹤0.01% 3987
2014
Q2 		$947K Sell
29,500
-2,200
-7% -$81.9K ﹤0.01% 4027
2014
Q1 		$1.46M Buy
31,700
+29,900
+1,661% +$1.75M ﹤0.01% 3505
2013
Q4 		$128K Sell
1,800
-1,000
-36% -$76.5K ﹤0.01% 5948
2013
Q3 		$240K Sell
2,800
-24,600
-90% -$2.09M ﹤0.01% 5295
2013
Q2 		$1.74M Buy
+27,400
New +$1.45M ﹤0.01% 3386

Bank of America's AEGR Position: Q4 2016 in Review

Bank of America sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 26,434 shares — an estimated $79K sold.

Bank of America first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $43.2M in Q3 2014. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.

  • Bank of America reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Bank of America sold 26,434 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $79K.
  • Bank of America first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
  • Bank of America's Aegerion Pharmaceuticals position peaked at $43.2M in Q3 2014.
  • 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.

Based on Bank of America's 13F filing for Q4 2016, filed 14 Feb 2017.